KR20220084095A - 알츠하이머병의 치료를 위한 항-베타-아밀로이드 항체 - Google Patents

알츠하이머병의 치료를 위한 항-베타-아밀로이드 항체 Download PDF

Info

Publication number
KR20220084095A
KR20220084095A KR1020227015913A KR20227015913A KR20220084095A KR 20220084095 A KR20220084095 A KR 20220084095A KR 1020227015913 A KR1020227015913 A KR 1020227015913A KR 20227015913 A KR20227015913 A KR 20227015913A KR 20220084095 A KR20220084095 A KR 20220084095A
Authority
KR
South Korea
Prior art keywords
antibody
subject
amount
disease
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227015913A
Other languages
English (en)
Korean (ko)
Inventor
헤벌라인 사만타 부드
잉 티안
라우라 니센바움
라지 라자고빈단
거샴 덴트
쟌 비버
에드워드 플로위
티에리 부시르
로저 니쉬
Original Assignee
바이오젠 엠에이 인코포레이티드
뉴리뮨 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오젠 엠에이 인코포레이티드, 뉴리뮨 아게 filed Critical 바이오젠 엠에이 인코포레이티드
Publication of KR20220084095A publication Critical patent/KR20220084095A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020227015913A 2019-10-22 2020-10-21 알츠하이머병의 치료를 위한 항-베타-아밀로이드 항체 Pending KR20220084095A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962924633P 2019-10-22 2019-10-22
US62/924,633 2019-10-22
PCT/US2020/056676 WO2021081101A1 (en) 2019-10-22 2020-10-21 Anti-beta-amyloid antibody for treating alzheimer's disease

Publications (1)

Publication Number Publication Date
KR20220084095A true KR20220084095A (ko) 2022-06-21

Family

ID=73344157

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227015913A Pending KR20220084095A (ko) 2019-10-22 2020-10-21 알츠하이머병의 치료를 위한 항-베타-아밀로이드 항체

Country Status (13)

Country Link
US (1) US20220372123A1 (https=)
EP (1) EP4048695A1 (https=)
JP (2) JP2022553329A (https=)
KR (1) KR20220084095A (https=)
CN (1) CN114599393A (https=)
AU (1) AU2020371612A1 (https=)
BR (1) BR112022007595A2 (https=)
CA (1) CA3158513A1 (https=)
CO (1) CO2022004902A2 (https=)
IL (1) IL292363A (https=)
JO (1) JOP20220092A1 (https=)
MX (1) MX2022004678A (https=)
WO (1) WO2021081101A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024089620A1 (en) * 2022-10-25 2024-05-02 Institute For Basic Science (Ibs) Extracranial methods for facilitating cerebrospinal fluid drainage

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2019152706A1 (en) 2018-01-31 2019-08-08 Alector Llc Anti-ms4a6a antibodies and methods of use thereof
US11472874B2 (en) 2018-01-31 2022-10-18 Alector Llc Anti-MS4A4A antibodies and methods of use thereof
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
TW202300517A (zh) * 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
TW202300518A (zh) * 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
WO2023081194A2 (en) * 2021-11-03 2023-05-11 Biogen Ma Inc. Methods for treating alzheimer's disease
AU2022439338A1 (en) * 2022-02-02 2024-08-15 Eisai R&D Management Co., Ltd. Methods of treatment using p-tau181 level
WO2024086796A1 (en) * 2022-10-20 2024-04-25 Alector Llc Anti-ms4a4a antibodies with amyloid-beta therapies
EP4455161A1 (en) 2023-04-24 2024-10-30 ONO Pharmaceutical Co., Ltd. Human-derived anti-collapsin response mediator protein 2 (crmp2) antibodies
TW202530246A (zh) 2023-09-15 2025-08-01 愛爾蘭商歐賽爾普羅希那有限公司 細胞穿透劑及其用途
WO2025117721A1 (en) * 2023-11-27 2025-06-05 Massachusetts Institute Of Technology Reconstituted lipoprotein particles to rescue lipid defects in the alzheimer's brain

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008081008A1 (en) 2007-01-05 2008-07-10 University Of Zurich Method of providing disease-specific binding molecules and targets
WO2008141321A1 (en) * 2007-05-14 2008-11-20 Medtronic, Inc. Methods and device to neutralize soluble toxic agents in the brain
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2598882B1 (en) * 2010-07-30 2017-07-26 AC Immune S.A. Safe and functional humanized antibodies for use in treating an amyloidosis
ME03008B (me) * 2011-09-19 2018-10-20 Axon Neuroscience Se Terapija na osnovu proteina i dijagnoza patologije u којој posreduje tau u alcнajмerovoj bolesti
US20150315267A1 (en) * 2012-12-07 2015-11-05 Thierry Bussiere A method of reducing brain amyloid plaques using anti-ab antibodies
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
CN114796481A (zh) * 2016-06-07 2022-07-29 生物基因国际神经科学有限责任公司 治疗阿尔茨海默病的方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024089620A1 (en) * 2022-10-25 2024-05-02 Institute For Basic Science (Ibs) Extracranial methods for facilitating cerebrospinal fluid drainage

Also Published As

Publication number Publication date
WO2021081101A1 (en) 2021-04-29
IL292363A (en) 2022-06-01
AU2020371612A1 (en) 2022-05-19
CA3158513A1 (en) 2021-04-29
JP2026012271A (ja) 2026-01-23
CO2022004902A2 (es) 2022-07-08
BR112022007595A2 (pt) 2022-08-23
JOP20220092A1 (ar) 2023-01-30
CN114599393A (zh) 2022-06-07
EP4048695A1 (en) 2022-08-31
US20220372123A1 (en) 2022-11-24
MX2022004678A (es) 2022-08-15
JP2022553329A (ja) 2022-12-22

Similar Documents

Publication Publication Date Title
KR20220084095A (ko) 알츠하이머병의 치료를 위한 항-베타-아밀로이드 항체
JP2023011002A (ja) アルツハイマー病の治療法
US20220281963A1 (en) Methods for treating alzheimer's disease
JP2025506389A (ja) ｐ－タウ１８１レベルを使用した治療方法
JP2024532438A (ja) 抗Ａβプロトフィブリル抗体の皮下製剤及びその使用方法
JP2024547001A (ja) 抗アミロイドβプロトフィブリル抗体及び抗タウ抗体を使用する方法
WO2023081194A2 (en) Methods for treating alzheimer's disease
TW202434629A (zh) 以抗類澱粉β (ABETA)抗體治療神經病症之方法
TW202313111A (zh) 治療阿茲海默症之方法
CN117999094A (zh) 抗Aβ初原纤维抗体的皮下配制品及其使用方法
TW202541846A (zh) 以抗類澱粉蛋白β (ABETA)抗體治療神經病症之方法
WO2025240435A1 (en) Methods of treating neurological disorders with anti-abeta antibodies
KR20260022396A (ko) 항-Aβ 프로토피브릴 항체를 사용한 치료 방법
WO2026015877A1 (en) Fluid biomarker
EA052963B1 (ru) Способы применения антитела к протофибриллам бета-амилоида и антитела к тау-белку
NZ788486A (en) Methods for treating Alzheimer's disease

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13 Search requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D13-SRH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000